154 related articles for article (PubMed ID: 12391539)
1. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models.
Corthay A; Lundin KU; Munthe LA; Frøyland M; Gedde-Dahl T; Dembic Z; Bogen B
Cancer Immunol Immunother; 2004 Sep; 53(9):759-69. PubMed ID: 15088126
[TBL] [Abstract][Full Text] [Related]
4. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
5. Deletion of idiotype (Id)-specific T cells in multiple myeloma.
Bogen B; Schenck K; Munthe LA; Dembic Z
Acta Oncol; 2000; 39(7):783-8. PubMed ID: 11145433
[TBL] [Abstract][Full Text] [Related]
6. Clonal deletion of thymocytes as a tumor escape mechanism.
Lauritzsen GF; Hofgaard PO; Schenck K; Bogen B
Int J Cancer; 1998 Oct; 78(2):216-22. PubMed ID: 9754655
[TBL] [Abstract][Full Text] [Related]
7. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
Lauritzsen GF; Bogen B
Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
[TBL] [Abstract][Full Text] [Related]
8. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
9. Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells.
Jacobsen J; Haabeth OA; Tveita AA; Schjetne KW; Munthe LA; Bogen B
J Immunol; 2014 May; 192(9):4174-83. PubMed ID: 24706724
[TBL] [Abstract][Full Text] [Related]
10. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
Bogen B
Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
[TBL] [Abstract][Full Text] [Related]
11. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
[TBL] [Abstract][Full Text] [Related]
12. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
13. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
14. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
[TBL] [Abstract][Full Text] [Related]
15. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
18. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Wen YJ; Barlogie B; Yi Q
Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
[TBL] [Abstract][Full Text] [Related]
19. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
Cohen S; Haimovich J; Hollander N
J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
Ghosh SK; White LM; Ghosh R; Bankert RB
J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]